CAS 1421373-62-7

Mutant EGFR inhibitor

CAS: 1421373-62-7

Mutant EGFR inhibitor

Reinheit: ≥95%

Molekulargewicht: 520.03g/mol

Ref: 54-BUP12357

Mutant EGFR inhibitor

CAS: 1421373-62-7

Selective, potent inhibitor for mutated EGFR: L858R, Exon19 deletion, T790M resistance mutants.

Formel: C₂₇H₃₀ClN₇O₂

Reinheit: 98% - 99.75%

Farbe und Form: Solid

Molekulargewicht: 520.03

Ref: TM-T2705

Mutant EGFR inhibitor

CAS: 1421373-62-7

Mutant EGFR inhibitor is a targeted therapeutic agent, which is a pharmaceutical compound originating from advanced drug discovery platforms. Its mode of action involves the selective inhibition of epidermal growth factor receptor (EGFR) proteins that carry specific mutations, such as L858R or exon 19 deletions, often implicated in tumorigenesis. By binding to the ATP-binding site of the mutant EGFR, this inhibitor prevents the phosphorylation cascade necessary for downstream signaling, effectively blocking pathways involved in cell proliferation and survival.

Formel: C₂₇H₃₀ClN₇O₂

Reinheit: Min. 95%

Molekulargewicht: 520.03 g/mol

Ref: 3D-WGC37362